In the second of a two-part series, we look at key trial design features FDA is expected to require of any future Phase 3 study from Lykos. Here, we run through how the MDMA drug developer will be…| Psychedelic Alpha
Following last week’s negative headlines, we review how Lykos Therapeutics unsuccessfully sought to reassure the committee, how its apparent policy of minimal engagement might have backfired…| Psychedelic Alpha
We provide information, research, news and exclusive interviews from the emergent psychedelic sector in one place. Cut through the ‘shroom stock’ noise with Psilocybin Alpha.| Psychedelic Alpha
Your one-stop source for the latest coverage of psychedelics in the media: from policy and culture through to research and business.| Psychedelic Alpha
Q3 2025 saw just over $120M flow into psychedelics companies, with atai Life Sciences, Reunion Neuroscience, and Sensorium Therapeutics leading the way. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q3 roundup.| Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical context from LSD and “truth serum” sessions to the Satanic Panic, the renewed debate sparked by a recent New York Times feature, and the clinical and ethical challenges posed by so-called “recovered” memories under psychedelics.| Psychedelic Alpha
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing October 6, 2025.| Psychedelic Alpha
Oregon Psilocybin Services (OPS) has now published its second dataset for 2025, with updates summarised in our Oregon Psilocybin Services Tracker. Here, we share a summary of the main takeaways for Pα+ subscribers.| Psychedelic Alpha
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.| Psychedelic Alpha
Topline results from the latest in our series of psychedelics investor surveys. For detailed analysis, subscribe to Pα+ today.| Psychedelic Alpha
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.| Psychedelic Alpha
Dispatch: Borealis Summit Puts Compass Pathways’ Minimal Support Model Under Microscope • IV Ketamine Outperforms IN Esketamine in Retrospective Study • Reunion Neuroscience Advances RE104 While Academic Preclinical Study of Psilocybin Raises Postpartum Questions • Mindstate Design Labs Completes Phase I Study, Teases First Fixed-Dose Combination Program • New York Assembly Discusses Psilocybin • and more…| Psychedelic Alpha
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 22, 2025.| Psychedelic Alpha
atai Wins $11.4M NIDA Grant to Develop Non-Hallucinogenic Psychedelics for OUD • Australia’s Largest Private Health Insurer Funds Psilocybin for Treatment-Resistant Depression Pilot • Osmind and Bendable Share Real-World Outcomes from 88 Psilocybin Clients • Psychedelic Pipeline Bullseye Chart Update Log • Pennsylvania Lawmakers Talk Psychedelics in Hearing on Treatment-Resistant Depression • Reunion Upsizes Series A to $133M Following Phase 2 Success • Virtual Ketamine Startup ...| Psychedelic Alpha
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…| Psychedelic Alpha
This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…| Psychedelic Alpha
We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.| Psychedelic Alpha
From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…| Psychedelic Alpha
Explore our interactive database of psychedelic patent activity in August 2025 via our Pα+ interface.| Psychedelic Alpha
Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the…| Psychedelic Alpha
FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.| Psychedelic Alpha
The FDA is pushing researchers to reduce their use of animal models and instead adopt ‘new approach methodologies’, like organoids and AI modelling. Here, Dr. Alaina Jaster speaks with psychedelic…| Psychedelic Alpha
One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth…| Psychedelic Alpha
Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.| Psychedelic Alpha
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany’…| Psychedelic Alpha
Here, we share Dr. Alaina Jaster’s observations from the inaugural Neurobiology of Psychedelics Gordon Research Conference, where leading scientists gathered to explore various realms of psychedelic…| Psychedelic Alpha
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. ∎ Pα+ is read by the world’s leading drug…| Psychedelic Alpha
Work with Psychedelic Alpha’s Josh Hardman and his network of subject matter experts: from well-defined consultancy projects and regular advisory sessions through to idea development and venture…| Psychedelic Alpha
NASDAQ-listed psychedelic drug developer atai Life Sciences has announced a strategic investment in—and collaboration with—its British privately-held peer, Beckley Psytech. The former will own a 35.5%| Psychedelic Alpha
